



ORAGENICS

SMaRT Replacement Therapy Featured on Channel 2 KTVU San Francisco

On May 31, 2007, Channel 2 KTVU in San Francisco aired a health segment by John Fowler entitled "Breakthrough New Cavity Treatment" that featured Oragenics' SMaRT Replacement Therapy™. The segment will be on KTVU's website for another week and if you would like to see the segment that was aired, the website address for the video is:

<http://www.ktvu.com/video/13423612/index.html>

Oragenics is currently working on our most recent protocol submission for SMaRT Replacement Therapy™ to make the revisions requested by the FDA and while we have no guarantees, we are hoping to receive approval to begin clinical trials in the 3rd quarter of 2007.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics' core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Contact:

Oragenics, Inc.

Robert T. Zahradnik, 386-418-4018 X222

www.oragenics.com

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project", and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.